REIG JOFRE publishes its 2025 full year financial results
REIG JOFRE CLOSES 2025 WITH €331.1M AND STRENGTHENS ITS INDUSTRIAL AND BIOTECH PLATFORM FOR THE NEXT GROWTH CYCLE
2025 Highlights
- Revenue: €331.1M (-2% vs. 2024)
- Antibiotics (Toledo): representing 20% of total 2024 sales, a 30% decline in 2025 due to reduced capacity pulled overall revenue down to -2%, despite growth across the rest of the portfolio
- Gross margin: 59%, slightly above 2024, supported by a more profitable sales mix
- Reported EBITDA: €30.5M (9.2% margin)
- Consolidated net income: €5.0M, in a year marked by a change in consolidation scope and related accounting impacts
- Net debt: €101.1M; Net debt/EBITDA 3.3x (2.5x excluding Leanbio and Syna Therapeutics)
REIG JOFRE, (BME:RJF), closed 2025 with €331.1 million in revenue (-2% vs. 2024), in a year shaped by strategic progress across two key areas: industrial transformation and biotechnology. Consistent with its purpose of universalizing the science that matters, REIG JOFRE strengthened the capabilities that underpin scientific rigor, manufacturing excellence, and reliable supply. The year was defined by the modernization of manufacturing capacity, proactive regulatory readiness, and a stronger positioning in higher value-added segments, consolidating a more robust and competitive model, ready to take on the next cycle of expansion.
On the industrial front, REIG JOFRE prioritized productivity and efficiency. As part of this process, the temporary capacity reduction in the antibiotics business at its Toledo plant, resulting from the upgrade of two production lines to meet the new GMP requirements, serves a clear purpose: to prepare the facilities to support future growth and strengthen the reliability of supply in an essential area such as antibiotics.
In parallel, the technology pillar advanced through pipeline development and a stronger commitment to biotechnology, supported by product innovation and advanced pharmaceutical technologies. Participation in European initiatives such as EMINTECH and vertical integration with Leanbio position REIG JOFRE to capture higher value-added opportunities in the coming years, expanding its capabilities to support the patient journey from prevention through the most critical care.
From a business mix perspective, the strategic weight of the antibiotics business, representing 20% of REIG JOFRE’s activity in 2024, explains the drag from the 30% decline in 2025. The temporary capacity reduction in Toledo reduced a meaningful volume of sales that could not be fully offset by growth in injectables, Specialty Pharmacare, and Consumer Healthcare. As a result, full-year revenue finished down 2%, while REIG JOFRE continues to execute its industrial modernization plan to restore capacity, efficiency, and commercial momentum beginning in 2026.